Mimi Lo
Overview
Explore the profile of Mimi Lo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ragavan M, Swartz S, Clark M, Lo M, Gupta A, Chino F, et al.
JCO Oncol Pract
. 2024 Jan;
20(2):291-299.
PMID: 38175987
Purpose: Financial assistance (FA) programs are increasingly used to help patients afford oral anticancer medications (OAMs), but access to such programs and their impact on out-of-pocket (OOP) spending has not...
2.
Yang C, Khan F, MacDonald C, Guglielmo J, Lo M, Young R, et al.
J Thromb Thrombolysis
. 2023 Nov;
57(2):293-301.
PMID: 37932590
Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) treatment are of interest in oncology due to ease of administration and lack of need for therapeutic monitoring compared to other anticoagulants....
3.
Lee A, Badgley C, Lo M, Banez M, Graff L, Damon L, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1247-1253.
PMID: 37626267
Hematopoietic cell transplant (HCT) recipients are at risk for thromboembolic and bleeding complications. There is limited evidence regarding the optimal approach to managing venous thromboembolism (VTE) prophylaxis in hospitalized patients...
4.
Duvalyan E, Shah N, Lo M, Martin 3rd T, Wolf J, Chung A, et al.
Leuk Lymphoma
. 2023 Aug;
64(11):1888-1891.
PMID: 37599633
No abstract available.
5.
Lee J, Wagner C, Prelewicz S, Kurish H, Walchack R, Cenin D, et al.
Haematologica
. 2023 Jun;
108(12):3460-3463.
PMID: 37345485
No abstract available.
6.
Zafar A, Huang C, Lo M, Arora S, Chung A, Wong S, et al.
Transplant Cell Ther
. 2023 May;
29(8):504.e1-504.e7.
PMID: 37244643
Patients receiving autologous chimeric antigen receptor T cell (CAR-T) therapy for multiple myeloma (MM) may require bridging therapy (BT) before CAR-T infusion to maintain some level of disease control. Alkylators,...
7.
Reyes K, Huang C, Lo M, Arora S, Chung A, Wong S, et al.
Transplant Cell Ther
. 2023 Mar;
29(6):350-355.
PMID: 36933659
Risks of B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy for patients with multiple myeloma (MM) include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias,...
8.
Rath C, Yoo C, Cheplowitz H, Lo M, Young R, Guglielmo J, et al.
J Oncol Pharm Pract
. 2023 Feb;
29(7):1715-1724.
PMID: 36731514
Background: For patients with multiple myeloma (MM) who have undergone autologous stem cell transplant (auto-SCT), the immunomodulatory agent lenalidomide is a first-line option for maintenance therapy. Because longer durations of...
9.
Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, et al.
Leuk Lymphoma
. 2022 Jul;
63(12):3008-3011.
PMID: 35875857
No abstract available.
10.
Banerjee R, Lazar A, Dunn L, Knoche J, Lo M, Arora S, et al.
EJHaem
. 2022 Jul;
2(2):276-279.
PMID: 35845271
Multiple myeloma patients undergoing autologous stem cell transplantation (ASCT) may receive benzodiazepine or zolpidem-class (B/Z) medications despite their risks in older patients. Of 205 myeloma patients (36% aged 65+) who...